Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06621602 · ClinicalTrials.gov registry record
Quantification of Phosphorylated Alpha-synuclein in Cutaneous Biopsies as a Prospective Biomarker in Parkinson's Disease
A clinical trial of Parkinson Disease and REM Behavior Disorder, sponsored by CND Life Sciences.
- Active
- Registry status
- 100
- Enrollment target
- 18
- Study locations
NCT06621602: Active study of Parkinson Disease and REM Behavior Disorder, sponsored by CND Life Sciences.
NCT06621602 is a study of Parkinson Disease and REM Behavior Disorder that is active but no longer recruiting, run by CND Life Sciences. The registered enrollment target is 100 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (98% lower). The trial reports 18 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06621602, a study of Parkinson Disease and REM Behavior Disorder, is active but no longer recruiting, sponsored by CND Life Sciences.
- ACTIVE NOT RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 18
- Study locations
Study Summary
This study aims to assess the levels of phosphorylated alpha-synuclein (P-SYN) in patients with Parkinson's disease and REM Behavior Disorder using a minimally invasive skin punch biopsy. It seeks to understand the natural progression of P-SYN deposition over time to explore the potential of P-SYN quantification as a biomarker for disease progression.
Primary Outcome
The accuracy of the pathological test in detecting α-synuclein aggregation and deposition in skin punch biopsies. Measurement of the quantity of phosphorylated alpha-synuclein (P-SYN) in each biopsy to determine whether cutaneous biopsies can serve as a biomarker for changes in P-SYN deposition over time .
Conditions Studied
Study Locations (18)
California
- Parkinson's Research Centers of America - Orange County - Aliso Viejo
- Cedars Sinai - Los Angeles
- Parkinson's Research Centers of America - Palo Alto - Palo Alto
Arizona
- CND Life Sciences - Scottsdale
- Movement Disorders Center of Arizona - Scottsdale
Florida
- Aventura Neurologic Associates, LLC - Aventura
- Parkinson's Disease and Movement Disorders Center - Boca Raton - Boca Raton
New York
- Parkinson's Research Centers of America - Long Island - Commack
- University of Rochester - Rochester
Colorado
- University of Colorado - Aurora
Georgia
- Atlanta NeuroScience Institute ANI - Atlanta
Kansas
- Parkinson's Disease and Movement Disorders Center at KUMC - Kansas City
Kentucky
- Neurology Multidisciplinary Clinic at Norton Healthcare - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2024-12-17 |
| Est. Completion | 2027-04 |
What the registry record for NCT06621602 still lists
NCT06621602 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Parkinson Disease appearing as the primary indexed condition, and to 0 interventions.
NCT06621602 lists 18 locations in 13 states (California, Arizona, Florida).
Frequently Asked Questions
What is clinical trial NCT06621602 about?
NCT06621602 is a clinical study titled "Quantification of Phosphorylated Alpha-synuclein in Cutaneous Biopsies as a Prospective Biomarker in Parkinson's Disease". This study aims to assess the levels of phosphorylated alpha-synuclein (P-SYN) in patients with Parkinson's disease and REM Behavior Disorder using a minimally invasive skin punch biopsy. It seeks to understand the natural progression of P-SYN deposition over time to explore the potential of P-SYN q...
What is the current status of trial NCT06621602?
This trial is currently active not recruiting. The enrollment target is 100 participants. The study started on 2024-12-17. Estimated completion is 2027-04.
What conditions does trial NCT06621602 study?
This clinical trial studies the following conditions: Parkinson Disease, REM Behavior Disorder.
Who is sponsoring clinical trial NCT06621602?
This trial is sponsored by CND Life Sciences, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06621602 being conducted?
This trial has 18 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06621602's enrollment target sits among peer trials
100 86th of 297 higher than 207 of 297 other Parkinson Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of Correlation Between Oculometric Measures and Clinical Assessment in Parkinson's Disease
RECRUITING · NA
-
Colonoscopic Detection of Phosphorylated Alpha-synuclein for Parkinson's Diagnosis
RECRUITING
-
University of Delaware Parkinson's Disease Registry
RECRUITING
-
Neocortical Microarchitecture of Executive Function
RECRUITING · NA
-
Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)
RECRUITING · NA
-
Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI